Methods for treating tumors using antiangiogenic compounds
CA 2372699 A1 · Owner: The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services · Inventors: Libutti, Steven K.; Feldman, Andrew
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention provides a compound comprising a recombinant nucleic acid encoding an antiangiogenic protein inserted within a viral nucleic acid wherein the recombinant nucleic acid can be packaged in a virus particle and wherein expression of the recombinant nucleic acid encoding the antiangiogenic protein results in production of the antiangiogenic protein. The present invention also provides a method of delivering an antiangiogenic protein to a cell, delivering an antiangiogenic protein to a subject and treating a tumor , in a subject comprising administering a virus comprising a recombinant nucleic acid encoding an antiangiogenic protein inserted within the viral nucleic acid, …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 5, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 5, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 5, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.